Lymecycline
Brand names: Tetralysal 300
Lymecycline is an oral tetracycline antibiotic used mainly for moderate inflammatory acne vulgaris and sometimes rosacea.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It inhibits bacterial protein synthesis by binding the 30S ribosomal subunit and also has anti-inflammatory effects relevant to acne, including activity against Cutibacterium acnes.
Prescribing in practice
- Contraindicated in pregnancy, breastfeeding and in children under twelve because tetracyclines cause permanent dental discolouration and affect bone development; avoid in this group.
- It should not be taken at the same time as antacids, or iron, calcium, magnesium or zinc salts, which impair absorption through chelation.
- An adequate trial of several weeks is needed before judging response in acne, and benefit-risk should be reviewed for prolonged courses.
Monitoring
Monitor for clinical response and for adverse effects such as photosensitivity, gastrointestinal upset and, rarely, intracranial hypertension.
Counselling the patient
- Do not take if you are or could be pregnant, or if breastfeeding.
- Separate the capsule from indigestion remedies and iron, calcium or zinc supplements.
- Use sun protection, and seek urgent advice for severe headache with visual disturbance.
Evidence & guidelines
Oral tetracyclines including lymecycline are recommended in NICE guidance as an option for moderate-to-severe acne vulgaris, generally combined with a topical agent.
Reference: NICE NG198; BAD acne guidance; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Centor / McIsaac Score for Strep Pharyngitis · Throat
- FeverPAIN Score for Strep Throat · Throat
- Jarisch-Herxheimer Reaction Severity Assessment · Treatment Reactions
- PID Severity (CDC Diagnostic Criteria) · Gynaecological Infections
- Gustilo-Anderson Classification (Open Fractures) · Fracture Classification
- DRIP Score for Drug-Resistant Pneumonia · Pneumonia
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD